DK132303C - Fremgangsmade til fremstilling af en legemiddelform med retarderende virkning - Google Patents

Fremgangsmade til fremstilling af en legemiddelform med retarderende virkning

Info

Publication number
DK132303C
DK132303C DK101271A DK101271A DK132303C DK 132303 C DK132303 C DK 132303C DK 101271 A DK101271 A DK 101271A DK 101271 A DK101271 A DK 101271A DK 132303 C DK132303 C DK 132303C
Authority
DK
Denmark
Prior art keywords
procedure
preparation
pharmaceutical form
retaining effect
retaining
Prior art date
Application number
DK101271A
Other languages
Danish (da)
English (en)
Other versions
DK132303B (da
Inventor
W Fylberth
E Neitzer
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of DK132303B publication Critical patent/DK132303B/da
Application granted granted Critical
Publication of DK132303C publication Critical patent/DK132303C/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
DK101271A 1970-03-05 1971-03-04 Fremgangsmade til fremstilling af en legemiddelform med retarderende virkning DK132303C (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2010416A DE2010416B2 (de) 1970-03-05 1970-03-05 Oral anwendbare Arzneiform mit Retardwirkung

Publications (2)

Publication Number Publication Date
DK132303B DK132303B (da) 1975-11-24
DK132303C true DK132303C (da) 1976-04-26

Family

ID=5764197

Family Applications (1)

Application Number Title Priority Date Filing Date
DK101271A DK132303C (da) 1970-03-05 1971-03-04 Fremgangsmade til fremstilling af en legemiddelform med retarderende virkning

Country Status (13)

Country Link
US (1) US3835221A (it)
JP (1) JPS5331930B1 (it)
AT (1) AT305498B (it)
BE (1) BE763735A (it)
CA (1) CA977680A (it)
DE (1) DE2010416B2 (it)
DK (1) DK132303C (it)
ES (1) ES388698A1 (it)
FR (1) FR2085672B1 (it)
GB (1) GB1326995A (it)
NL (1) NL169680C (it)
SE (1) SE377886B (it)
ZA (1) ZA711412B (it)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1468172A (en) * 1973-03-28 1977-03-23 Benzon As Alfred Oral drug preparations
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
DE2343218C2 (de) * 1973-08-28 1986-08-07 Hoechst Ag, 6230 Frankfurt Furosemid enthaltende Pellets
FR2377196A1 (fr) * 1977-01-13 1978-08-11 Lipha Composition medicamenteuse a usage oral
GB1561204A (en) * 1977-06-01 1980-02-13 Ici Ltd Sustained release pharmaceutical composition
FR2397840B1 (it) * 1977-07-22 1981-03-20 Cherqui Jean
US4153677A (en) * 1978-05-18 1979-05-08 Sterling Drug Inc. Controlled-release composition
GB1584130A (en) * 1978-05-30 1981-02-04 Wyeth John & Brother Ltd Indole derivatives
DD146547A5 (de) * 1978-07-15 1981-02-18 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
SE426548B (sv) * 1978-12-05 1983-01-31 Haessle Ab Fast farmaceutisk beredning innehallande en terapeutiskt effektiv hjertglykosid och en polymer
US4173626A (en) * 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
SE7813246L (sv) * 1978-12-22 1980-06-23 Haessle Ab Fast farmaceutisk beredning innehallande kroppar med flera ytskikt
JPS55129219A (en) * 1979-03-29 1980-10-06 Asahi Chem Ind Co Ltd Slow-releasing preparation
FR2454804B1 (fr) * 1979-04-26 1986-11-21 Sanofi Sa Medicament a base de dihydroergotoxine et son procede de preparation
US4252786A (en) * 1979-11-16 1981-02-24 E. R. Squibb & Sons, Inc. Controlled release tablet
US4543370A (en) * 1979-11-29 1985-09-24 Colorcon, Inc. Dry edible film coating composition, method and coating form
FR2470599A1 (fr) * 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
SE8103843L (sv) * 1981-06-18 1982-12-19 Astra Laekemedel Ab Farmaceutisk mixtur
DE3126703A1 (de) 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
US4587118A (en) * 1981-07-15 1986-05-06 Key Pharmaceuticals, Inc. Dry sustained release theophylline oral formulation
DE3278491D1 (en) * 1981-07-15 1988-06-23 Key Pharma Sustained release theophyline
US4415547A (en) * 1982-06-14 1983-11-15 Sterling Drug Inc. Sustained-release pharmaceutical tablet and process for preparation thereof
EP0111560A4 (en) * 1982-06-14 1987-02-03 Key Pharma Sustained release aspirin.
US4508702A (en) * 1982-06-14 1985-04-02 Key Pharmaceuticals, Inc. Sustained release aspirin
US4557925A (en) * 1982-07-08 1985-12-10 Ab Ferrosan Membrane-coated sustained-release tablets and method
WO1984000295A1 (en) * 1982-07-09 1984-02-02 Key Pharma Sustained release quinidine dosage form
US4634587A (en) * 1982-07-09 1987-01-06 Key Pharmaceuticals, Inc. Sustained release quinidine dosage form
IE55745B1 (en) * 1983-04-06 1991-01-02 Elan Corp Plc Sustained absorption pharmaceutical composition
USRE33994E (en) * 1983-08-16 1992-07-14 Burroughs Wellcome Co. Pharmaceutical delivery system
GB8322007D0 (en) * 1983-08-16 1983-09-21 Wellcome Found Pharmaceutical delivery system
JPS6051106A (ja) * 1983-08-31 1985-03-22 Yamanouchi Pharmaceut Co Ltd 塩酸アモスラロ−ル持続性製剤
US4749575A (en) * 1983-10-03 1988-06-07 Bio-Dar Ltd. Microencapsulated medicament in sweet matrix
US4555399A (en) * 1983-11-18 1985-11-26 Key Pharmaceuticals, Inc. Aspirin tablet
DE3403329A1 (de) * 1984-02-01 1985-08-01 Horst Dr. 4019 Monheim Zerbe Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe
GB2159714B (en) * 1984-06-04 1988-05-05 Sterwin Ag Pharmaceutical composition of sparingly soluble medicament and method for its preparation
GB8414221D0 (en) * 1984-06-04 1984-07-11 Sterwin Ag Unit dosage form
US4769027A (en) * 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
DE3485618D1 (de) * 1984-08-17 1992-04-30 Wellcome Found Zusammensetzung zur kontrollierten abgabe eines wirkstoffes und ihre herstellung.
US4629619A (en) * 1984-09-05 1986-12-16 Ab Ferrosan Membrane-coated sustained-release tablets and method
US4629620A (en) * 1984-09-05 1986-12-16 Ab Ferrosan Membrane-coated sustained-release tablets and method
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4867984A (en) * 1984-11-06 1989-09-19 Nagin K. Patel Drug in bead form and process for preparing same
CA1268710A (en) * 1984-11-06 1990-05-08 Nagin K. Patel Drug in bead form and process for preparing same
US4728512A (en) * 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
US4666704A (en) * 1985-05-24 1987-05-19 International Minerals & Chemical Corp. Controlled release delivery system for macromolecules
US4904476A (en) * 1986-03-04 1990-02-27 American Home Products Corporation Formulations providing three distinct releases
US4794001A (en) * 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
US5286494A (en) * 1986-07-02 1994-02-15 Schering Aktiengesellschaft Medicinal agents with sustained action
JPS6327424A (ja) * 1986-07-17 1988-02-05 Shionogi & Co Ltd 徐放性製剤およびその製造法
US4752470A (en) * 1986-11-24 1988-06-21 Mehta Atul M Controlled release indomethacin
US4786509A (en) * 1987-05-18 1988-11-22 Schering Corporation Dry sustained release theophylline oral formulation
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5122384A (en) * 1989-05-05 1992-06-16 Kv Pharmaceutical Company Oral once-per-day organic nitrate formulation which does not induce tolerance
US5084287A (en) * 1990-03-15 1992-01-28 Warner-Lambert Company Pharmaceutically useful micropellets with a drug-coated core and controlled-release polymeric coat
US6638963B1 (en) 1990-12-04 2003-10-28 Oregon Health And Science University Methods for treating circadian rhythm disorders
US5707652A (en) * 1990-12-04 1998-01-13 State Of Oregon Methods of treating circadian rhythm phase disorders
US5252337A (en) * 1991-06-25 1993-10-12 Eurand America, Inc. Controlled release calcium channel blocker microcapsules
IL110035A0 (en) * 1994-06-16 1994-10-07 Tapuach Natural Technologies 1 Homeopathic formulations
US5744164A (en) * 1994-12-16 1998-04-28 Nestec S.A. Sustained release microparticulate caffeine formulation
US5834024A (en) * 1995-01-05 1998-11-10 Fh Faulding & Co. Limited Controlled absorption diltiazem pharmaceutical formulation
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
US20020182258A1 (en) * 1997-01-22 2002-12-05 Zycos Inc., A Delaware Corporation Microparticles for delivery of nucleic acid
FR2766367B1 (fr) * 1997-07-22 2000-03-31 Plantes Et Medecines Granules homeopathiques et procede de fabrication
DE19732903A1 (de) 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
UA69413C2 (uk) * 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US6723342B1 (en) 1999-02-08 2004-04-20 Fmc Corporation Edible coating composition
US6432448B1 (en) 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
US20050037086A1 (en) * 1999-11-19 2005-02-17 Zycos Inc., A Delaware Corporation Continuous-flow method for preparing microparticles
US20040185099A1 (en) * 2000-01-20 2004-09-23 Biovail Laboratories, Inc. Multiparticulate bisoprolol formulation
US6254888B1 (en) * 2000-01-28 2001-07-03 Boehringer Ingelheim Pharmaceuticals, Inc. Method for coating pharmaceutical dosage forms
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6635277B2 (en) 2000-04-12 2003-10-21 Wockhardt Limited Composition for pulsatile delivery of diltiazem and process of manufacture
AU6815901A (en) * 2000-06-02 2001-12-17 Zycos Inc Delivery systems for bioactive agents
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
BR0115585A (pt) 2000-11-28 2005-12-13 Fmc Corp Composições de revestimento de pronta liberação, endurecìvel, comestìvel, seca e, úmida, forma de dosagem sólida, e, método para revestir uma forma de dosagem sólida farmacêutica ou veterinária, confeito, semente, ração animal, fertilizante, comprimido de pesticida ou alimento
US6932861B2 (en) 2000-11-28 2005-08-23 Fmc Corporation Edible PGA coating composition
US20040234602A1 (en) 2001-09-21 2004-11-25 Gina Fischer Polymer release system
EP1429744A1 (en) * 2001-09-21 2004-06-23 Egalet A/S Morphine polymer release system
US20040005358A1 (en) * 2002-04-23 2004-01-08 Slugg Peter H. Modified-release vasopeptidase inhibitor formulation, combinations and method
US20040029959A1 (en) * 2002-08-08 2004-02-12 John Devane Isosorbide mononitrate compositions and methods of their use
WO2004084868A1 (en) 2003-03-26 2004-10-07 Egalet A/S Morphine controlled release system
CA2611081C (en) * 2005-06-03 2016-05-31 Egalet A/S A drug delivery system for delivering active substances dispersed in a dispersion medium
PT1919458E (pt) 2006-01-27 2012-08-23 Univ California Cisteamina revestida entericamente, cisteamina e seus derivados
NZ577560A (en) * 2007-01-16 2012-01-12 Egalet Ltd Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
EP2155167A2 (en) 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
MX2010011209A (es) 2008-04-24 2010-11-12 Squibb Bristol Myers Co Uso de epotilona d en el tratamiento de enfermedades asociadas a tau incluyendo enfermedad de alzheimer.
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
NZ597283A (en) 2009-06-24 2013-07-26 Egalet Ltd Controlled release formulations
ES2555927T3 (es) 2011-01-20 2016-01-11 Bionevia Pharmaceuticals Inc. Composiciones de liberación modificada de epalrestat o un derivado del mismo y métodos para el uso de las mismas
RU2638807C2 (ru) 2011-11-22 2017-12-15 Те Риджентс Оф Те Юниверсити Оф Калифорния Способы и композиции для лечения воспаления и ишемического поражения
WO2013191965A1 (en) 2012-06-18 2013-12-27 Principia Biopharma Inc. Reversible covalent pyrrolo- or pyrazolopyrimidines useful for the treatment cancer and autoimmune diseases
US20150140085A1 (en) 2012-06-29 2015-05-21 Principia Biopharma Inc. Formulations comprising ibrutinib
BR112015000150A2 (pt) 2012-07-06 2017-06-27 Egalet Ltd composições farmacêuticas dissuasoras de abuso de liberação controlada
TWI649100B (zh) 2013-06-17 2019-02-01 地平線罕見醫學製藥有限責任公司 延遲釋放型半胱胺珠粒調配物，以及其製備及使用方法
PT3236953T (pt) 2014-12-24 2021-01-29 Principia Biopharma Inc Dosagem específica de sítio de um inibidor de btk
UA124090C2 (uk) 2015-06-03 2021-07-21 Прінсіпіа Байофарма Інк. Інгібітори тирозинкінази
WO2016210165A1 (en) 2015-06-24 2016-12-29 Principia Biopharma Inc. Tyrosine kinase inhibitors
EP3316877B1 (en) 2015-07-02 2019-10-30 Horizon Orphan LLC Ado-resistant cysteamine analogs and uses thereof
US10143665B2 (en) 2015-11-17 2018-12-04 Horizon Orphan Llc Methods for storing cysteamine formulations and related methods of treatment
PE20181521A1 (es) * 2015-12-08 2018-09-24 Ardea Biosciences Inc Composicion farmaceutica que comprende un potente inhibidor de urat1
CN115054586B (zh) 2016-06-29 2024-08-02 普林斯匹亚生物制药公司 改性的释放制剂
BR112022014058A2 (pt) 2020-01-20 2022-09-13 Genzyme Corp Inibidores terapêuticos de tirosina cinase para esclerose múltipla recidivante (rms)
TW202203934A (zh) 2020-04-17 2022-02-01 美商健臻公司 治療涉及全身過度發炎性反應的病症的受體相互作用蛋白激酶抑制劑
US20240124857A1 (en) 2021-02-19 2024-04-18 Dupont Nutrition Biosciences Aps Composition for gut health
BR112023015272A2 (pt) 2021-02-23 2023-11-07 Otsuka Pharma Co Ltd Formulações farmacêuticas de centanafadina e métodos de fabricação e uso das mesmas
CA3260159A1 (en) 2022-06-30 2024-01-04 Principia Biopharma Inc. Therapeutic Tyrosine Kinase Inhibitors for the Treatment of Multiple Sclerosis and Myasthenia Gravis
WO2024040043A1 (en) 2022-08-16 2024-02-22 International N&H Denmark Aps Expression systems for phosphatases
US20250375418A1 (en) 2022-09-02 2025-12-11 Otsuka Pharmaceutical Co., Ltd. 1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane for treating major depressive disorder
US20260092088A1 (en) 2022-09-20 2026-04-02 International N&H Denmark Aps Variant anti-viral polypeptides
EP4601647A1 (en) 2022-10-11 2025-08-20 Principia Biopharma Inc. Therapeutic tyrosine kinase inhibitors for multiple sclerosis
WO2025064636A1 (en) 2023-09-20 2025-03-27 Danisco Us Inc. Composition comprising an atp degrading enzyme and uses thereof
WO2025080755A1 (en) 2023-10-13 2025-04-17 Nutrition & Biosciences USA 4, Inc. Methods and compositions for aging and mitochondrial health
WO2026050513A1 (en) 2024-08-30 2026-03-05 Principia Biopharma Inc. Tolebrutinib for multiple sclerosis

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2410417A (en) * 1944-03-04 1946-11-05 Lever Brothers Ltd Vitamin and mineral dietary supplement and method of making
CH283585A (de) * 1950-03-15 1952-06-15 Hoffmann La Roche Zur Herstellung von Tablettenüberzügen geeignetes Gemisch.
FR1017117A (fr) * 1950-05-04 1952-12-02 Trialgol Lab Procédé de conditionnement à l'état de poudre de substances destinées à l'ingestion et produits en résultant
US2996431A (en) * 1953-12-16 1961-08-15 Barry Richard Henry Friable tablet and process for manufacturing same
US2811483A (en) * 1954-12-09 1957-10-29 Pfizer & Co C Pharmaceutical composition and process for preparing the same
US2853420A (en) * 1956-01-25 1958-09-23 Lowey Hans Ethyl cellulose coatings for shaped medicinal preparations
US2852433A (en) * 1956-03-07 1958-09-16 Eastman Kodak Co Method of making enteric medicament compositions
US2928770A (en) * 1958-11-28 1960-03-15 Frank M Bardani Sustained action pill
US3096248A (en) * 1959-04-06 1963-07-02 Rexall Drug & Chemical Company Method of making an encapsulated tablet
DE1228757B (de) * 1962-06-28 1966-11-17 Haessle Ab Verfahren zur Herstellung eines in Wasser und Magensaft rasch zerfallenden UEberzuges auf festen Arzneiformen
US3247066A (en) * 1962-09-12 1966-04-19 Parke Davis & Co Controlled release dosage form containing water-swellable beadlet
US3325365A (en) * 1963-04-02 1967-06-13 Ciba Geigy Corp Enteric composition for tablet compression coating
DE1216486B (de) * 1964-04-23 1966-05-12 Merck Ag E Verfahren zur Herstellung von Dragees
US3365365A (en) * 1965-08-09 1968-01-23 Hoffmann La Roche Repeat action pharmaceutical compositions in the form of discrete beadlets
US3538214A (en) * 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets

Also Published As

Publication number Publication date
CA977680A (en) 1975-11-11
BE763735A (fr) 1971-09-03
US3835221A (en) 1974-09-10
NL7102590A (it) 1971-09-07
NL169680B (nl) 1982-03-16
SE377886B (it) 1975-08-04
DK132303B (da) 1975-11-24
ES388698A1 (es) 1974-02-16
ZA711412B (en) 1971-11-24
NL169680C (nl) 1982-08-16
DE2010416B2 (de) 1979-03-29
JPS5331930B1 (it) 1978-09-05
DE2010416A1 (de) 1971-09-16
FR2085672B1 (it) 1974-04-12
FR2085672A1 (it) 1971-12-31
GB1326995A (en) 1973-08-15
AT305498B (de) 1973-02-26

Similar Documents

Publication Publication Date Title
DK132303C (da) Fremgangsmade til fremstilling af en legemiddelform med retarderende virkning
DK513578A (da) Fremgangsmaade til fremstilling af triazolylbenzopenoner
DK163482A (da) Mellemprodukt til fremstilling af alfa-aminopenicillinestere
DK146434C (da) Fremgangsmaade til fremstilling af tabletter eller suppositorier med langvarig frigoerelse
DK135699C (da) Fremgangsmaade til fremstilling af lynlaase
DK150981C (da) Fremgangsmaade til fremstilling af diesterdiamider
DK139966C (da) Fremgangsmaade til fremstilling af 1-hydroxy-2-pyridoner
DK136062C (da) Fremgangsmade til fremstilling af 2-alkylamino-dihydropyridiner
DK560675A (da) Fremgangsmade til fremstilling af thiopyrimidinderivater
SE397087B (sv) Forfarande for framstellning av substituerade pgf-prostaglandinforeningar med lekemedelsverkan
DK134782C (da) Fremgangsmade til fremstilling af 3beta-hydroxy-5beta-h-steroider
DK132586C (da) Fremgangsmade til fremstilling af erythromycylaminer
DK143847C (da) Analogifremgangsmaade til fremstilling af imidazolderivater
RO70179A (ro) Procedeu pentru prepararea izoprenului
DK145540C (da) Fremgangsmaade til fremstilling af eventuelt i oploest form foreliggende cholinsalicylatsulfitholdige forbindelser
SE380795B (sv) Forfarande for framstellning av tiokarbamider
DK139270B (da) Fremgangsmaade til fremstilling af alfakobberphthalocyanin
DK131786C (da) Fremgangsmade til fremstilling af delta4-3-oxo-1alfa-methylsteroider
DK140551B (da) Fremgangsmaade til fremstilling af diazabicycloalkanderivater
DK132887C (da) Analogifremgangsmade til fremstilling af tetrahydropyridinderivater
DK139577C (da) Fremgangsmaade til fremstilling af des-phenylalaninb1-insulin
DK144872C (da) Fremgangsmaade til fremstilling af pyrazolonholdige tabletter
DK135131C (da) Analogifremgangsmade til fremstilling af 6alfa,16alfa-dimethyl-1,4-pregnadien-3,20-dioner
DK133777C (da) Fremgangsmade til fremstilling af alfa-oximinonitriler
DK132175C (da) Fremgangsmade til fremstilling af penicillinsalte